EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023

News provided by

May 13, 2014, 09:30 ET

NEW YORK, May 13, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023

http://www.reportlinker.com/p02114381/EpiCast-Report-Amyotrophic-Lateral-Sclerosis---Epidemiology-Forecast-to-2023.html

Summary

Amyotrophic lateral sclerosis (ALS), often referred to as "Lou Gehrig's Disease," is a rare, but fatal, progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of ALS in the 7MM will grow by 13.5% over the next decade, from 32,698 diagnosed prevalent cases in 2013 to 37,122 diagnosed prevalent cases in 2023. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan.

To develop the epidemiological forecast for the diagnosed prevalent cases of ALS in the 7MM, GlobalData epidemiologists obtained the diagnosed prevalence data for ALS from peer-reviewed journals and population-based studies in the respective markets and used a consistent methodology to ensure comparability of the results. A major strength of GlobalData's epidemiological analysis is the use of country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets. Furthermore, the diagnosed prevalent cases of ALS in each of the 7MM were further segmented by age and sex in order to provide a more detailed analysis of the patient population.

Scope

- The Amyotrophic lateral sclerosis (ALS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of ALS segmented by age (=40 years) and sex in these markets.
- The ALS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global ALS market.
- Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ALS therapeutics in each of the markets covered.
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 7

3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global Trends 9
3.3.1 US 10
3.3.2 5EU 11
3.3.3 Japan 13
3.4 Forecast Methodology 13
3.4.1 Sources Used 14
3.4.2 Sources Not Used 17

3.4.3 Forecast Assumptions and Methods 18
3.5 Epidemiological Forecast for Amyotrophic Lateral Sclerosis (2013-2023) 21
3.5.1 Diagnosed Prevalent Cases of ALS 21
3.5.2 Age-Specific Diagnosed Prevalent Cases of ALS 22
3.5.3 Sex-Specific Diagnosed Prevalent Cases of ALS 24
3.5.4 Age-Standardized Diagnosed Prevalence of ALS 26
3.6 Discussion 27
3.6.1 Epidemiological Forecast Insight 27

3.6.2 Limitations of the Analysis 28
3.6.3 Strengths of the Analysis 29
4 Appendix 30
4.1 Bibliography 30
4.2 About the Authors 33
4.2.1 Epidemiologists 33
4.2.2 Reviewers 33
4.2.3 Global Director of Epidemiology and Health Policy 34
4.2.4 Global Head of Healthcare 35
4.3 About GlobalData 36
4.4 About EpiCast 36
4.5 Disclaimer 37

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for ALS 9
Table 2: Incidence (Cases per 100,000 Population) of ALS in the US, as Reported in Epidemiological Studies 10
Table 3: Prevalence (Cases per 100,000 Population) of ALS in the US, as Reported in Epidemiological Studies 11
Table 4: Incidence (Cases per 100,000 Population) of ALS in the European Markets, as Reported in Epidemiological Studies 12
Table 5: Prevalence (Cases per 100,000 Population) of ALS in the European Markets, as Reported in Epidemiological Studies 12
Table 6: El Escorial Diagnostic Criteria for ALS 13
Table 7: 7MM, Sources of Diagnosed Prevalence Data Used to Forecast the Diagnosed Prevalent Cases of ALS 14
Table 8: 7MM, Diagnosed Prevalent Cases of ALS, Age ?40 Years, Both Sexes, N, 2013-2023 21
Table 9: 7MM, Diagnosed Prevalent Cases of ALS, by Age, Both Sexes, N, (Row %), 2013 23
Table 10: 7MM, Diagnosed Prevalent Cases of ALS, by Sex, Age ?40 years, N (Row %), 2013 25

1.2 List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of ALS, Age ?40 Years, Both Sexes, N, 2013-2023 22
Figure 2: 7MM, Diagnosed Prevalent Cases of ALS, by Age, Both Sexes, N, 2013 24
Figure 3: 7MM, Diagnosed Prevalent Cases of ALS, by Sex, Age ?40 Years, N, 2013 25
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence (%) of ALS, Age ?40 Years, 2013 27

To order this report: EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023
http://www.reportlinker.com/p02114381/EpiCast-Report-Amyotrophic-Lateral-Sclerosis---Epidemiology-Forecast-to-2023.html

_________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker